Servier, a French bio/pharmaceutical company, has completed its $2.5-billion acquisition of Day One Biopharmaceuticals, a Brisbane, California-based bio/pharmaceutical developing oncology drugs. The companies had announced the acquisition last month (March 2026).  

Day One’s portfolio includes Ojemda (tovorafenib), an FDA-approved medicine for treating pediatric low-grade glioma, the most common form of tumors found in children. Day One currently markets the product in the US and has licensed the rights outside the US to Ipsen. 

In addition to tovorafenib, which is being investigated in additional indications, Day One’s pipeline includes Emi-Le (emiltatug ledadotin), an antibody drug conjugate and DAY301, a targeted therapy for treating certain rare cancers.  

Source: Servier